Source of Glossary of peptide terminology

{{Infobox list | name = Glossary of peptide terminology | subtitle = Reference material | Scope = Terms used across this wiki | Arrangement = By domain, then alphabetically }} This '''glossary''' defines terms used across PeptidePedia Wiki. Each entry gives a short definition and, where a full article exists, links to it. Terms are grouped by domain and ordered alphabetically within each group.{{r|usp1503}} Definitions here are deliberately brief. Where a term carries a distinction that matters — purity against content, sterility against endotoxin freedom, contraindication against warning — the entry states the distinction and the article develops it.{{r|usp621}} The glossary is not a substitute for the articles and does not attempt completeness.{{r|reports}} == Chemistry and manufacture == ; Aib : α-aminoisobutyric acid, a non-proteinogenic residue used to block [[Dipeptidyl peptidase-4|DPP-4]] cleavage. ; Acylation : Attachment of a fatty acid to a peptide, usually for [[Albumin binding half-life extension|albumin binding]]. ; Crude : The material obtained directly after [[Resin cleavage|cleavage]], before purification. See [[Crude peptide]]. ; Deletion sequence : A synthesis by-product missing one or more residues. ; [[Fmoc chemistry|Fmoc]] : The base-labile temporary protecting group scheme dominating peptide synthesis. ; Linker : The resin attachment defining the C-terminal functionality of the finished peptide. ; Lyophilisation : Freeze-drying; the isolation step producing the powder in a vial. See [[Lyophilisation]]. ; [[Solid-phase peptide synthesis|SPPS]] : Assembly of a peptide on an insoluble support. ; [[Trifluoroacetate counterion|TFA salt]] : The salt form in which most reverse-phase-purified peptides are isolated.{{r|usp1503}} == Analysis and documentation == ; [[Area percent purity|Area percent]] : Main-peak area over total integrated area; normalised, and independent of quantity. ; [[Batch number|Batch number]] : The identifier linking a container to production records. ; [[Certificate of analysis|COA]] : The document a supplier issues reporting determinations on a lot. ; [[Bacterial endotoxin test|Endotoxin]] : Lipopolysaccharide from Gram-negative bacteria; survives sterilisation. ; [[Karl Fischer titration|Karl Fischer]] : A water-specific determination, as distinct from [[Loss on drying|loss on drying]]. ; [[Limit of detection|LOD]] : The lowest level at which presence can be distinguished from background. ; [[Peptide content|Peptide content]] : The mass fraction of a solid that is peptide; not purity. ; [[Reference standard|Reference standard]] : A characterised material of assigned content used for calibration. ; [[Retention time|Retention time]] : Time from injection to peak; characteristic under fixed conditions. ; Stability-indicating : Of a method, able to resolve degradation products from the parent.{{r|usp621}} == Clinical and evidence == ; [[Placebo-adjusted effect|Placebo-adjusted]] : The difference between treatment and comparator arms. ; [[Intention-to-treat analysis|ITT]] : Analysis by randomised assignment, regardless of treatment received. ; [[Number needed to treat|NNT]] : Reciprocal of the absolute risk reduction, over a stated period. ; [[Surrogate endpoint|Surrogate endpoint]] : A measure standing in for an outcome of direct importance. ; Estimand : A precise statement of the quantity a trial estimates, including how discontinuation is handled. ; Contraindication : A circumstance in which labelling directs a product is not used; distinct from a warning. ; [[Research use only|Research use only]] : A presentation, not a quality grade; such material is not approved for human use.{{r|drucker2018}} Additional terms are defined where they first appear in the articles. Suggestions for entries belong on the talk page.{{r|reports}} == References == {{reflist}} <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> <ref name="usp621">United States Pharmacopeia, General Chapter <621>, ''Chromatography''.</ref> <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> == See also == * [[Peptide]] * [[Certificate of analysis]] * [[Area percent purity]] * [[Peptide content]] * [[International nonproprietary name]] {{DEFAULTSORT:Glossary of peptide terminology}} [[Category:Glossaries]] [[Category:Reference material]] [[Category:PeptidePedia Wiki administration]]